Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Risk & Volatility
Pasithea Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.63, suggesting that its stock price is 263% more volatile than the S&P 500.
Profitability
This table compares Pasithea Therapeutics and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pasithea Therapeutics | N/A | -85.48% | -77.42% |
| Onconetix | -1,717.50% | 8.24% | 2.90% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pasithea Therapeutics | N/A | N/A | -$20.43 million | ($3.57) | -0.20 |
| Onconetix | $810,000.00 | 0.99 | -$14.03 million | ($216.73) | -0.01 |
Onconetix has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Pasithea Therapeutics and Onconetix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pasithea Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 316.67%. Given Pasithea Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Onconetix.
Institutional and Insider Ownership
23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 1.0% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Pasithea Therapeutics beats Onconetix on 7 of the 13 factors compared between the two stocks.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
